论文部分内容阅读
目的探讨胸腺肽对于重症肺炎合并脓毒血症患者的临床治疗效果。方法 70例重症肺炎合并脓毒血症患者按照随机数字表法分为实验组和对照组,各35例。对照组患者给予常规综合治疗,实验组患者在此基础上给予胸腺肽治疗,比较两组患者临床疗效、各项转归时间以及治疗后各项检测指标变化情况。结果实验组患者显效率97.14%显著高于对照组80.00%,差异具有统计学意义(P<0.05);实验组患者机械通气停用时间、血管活性药物停用时间、休克逆转时间均显著短于对照组[(84.17±20.07)h VS(141.76±22.48)h、(3.18±1.16)d VS(6.37±1.73)d、(80.75±22.57)h VS(124.49±25.84)h],差异具有统计学意义(P<0.05);实验组患者治疗后呼吸频率(RR)、心率(HR)、白细胞计数(WBC)、降钙素原(PCT)、白细胞介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)水平均显著低于对照组[(18.06±1.17)次/min VS(20.33±1.75)次/min、(72.44±7.13)次/min VS(80.34±7.46)次/min、(7.51±1.11)×109/L VS(9.79±1.38)×109/L、(1.19±0.08)ng/L VS(1.49±0.20)ng/L、(122.74±15.58)ng/L VS(153.08±17.62)ng/L、(7.99±0.44)ng/L VS(9.18±0.61)ng/L],差异具有统计学意义(P<0.05)。结论胸腺肽能够有效提高重症肺炎合并脓毒血症的临床疗效,缩短转归时间,降低PCT、IL-6、TNF-α水平,临床效果显著,价值较高。
Objective To investigate the clinical effect of thymosin on patients with severe pneumonia complicated with sepsis. Methods Seventy patients with severe pneumonia complicated with sepsis were divided into experimental group and control group according to random number table method, 35 cases each. Patients in the control group were given conventional comprehensive treatment. Patients in the experimental group were given thymopeptide on this basis. The clinical curative effect, the prognosis of the two groups and the changes of the detection indexes after the treatment were compared. Results The effective rate of experimental group was 97.14%, which was significantly higher than that of control group (80.00%), the difference was statistically significant (P <0.05). The experimental group was significantly shorter than the duration of mechanical ventilation withdrawal, vasoactive drug withdrawal and shock reversal (84.17 ± 20.07) h VS (141.76 ± 22.48) h, (3.18 ± 1.16) d VS (6.37 ± 1.73) d, (80.75 ± 22.57) h VS (124.49 ± 25.84) h] in the control group. The difference was statistically significant (P <0.05). The respiratory rate (RR), heart rate (HR), white blood cell count (WBC), PCT, IL-6 and tumor necrosis (18.06 ± 1.17) times / min VS (20.33 ± 1.75) times / min, (72.44 ± 7.13) times / min VS (80.34 ± 7.46) times / min, min, 7.51 ± 1.11 × 109 / L VS 9.79 ± 1.38 × 109 / L, 1.19 ± 0.08 ng / L vs 1.49 ± 0.20 ng / L vs 122.74 ± 15.58 ng / L vs 153.08 ± 17.62) ng / L, (7.99 ± 0.44) ng / L VS (9.18 ± 0.61) ng / L, respectively, with statistical significance (P <0.05). Conclusion Thymosin can effectively improve the clinical efficacy of severe pneumonia with sepsis, shorten the prognosis and reduce the levels of PCT, IL-6 and TNF-α. The clinical effect is significant and the value is high.